← Back to Search

Extracorporeal Support

ECMO Methods for Lung Disease (REVOLUTION Trial)

N/A
Waitlist Available
Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients undergoing lung transplant surgery
Be older than 18 years old
Must not have
Moderate to severe right ventricular (RV) hypokinesis or dysfunction
Patients requiring concomitant cardiac surgery: For example, significant coronary artery disease (CAD) requiring surgical grafting
Timeline
Screening 3 weeks
Treatment Varies
Follow Up beginning from the arrival to the intensive care unit immediately after surgery
Awards & highlights
No Placebo-Only Group

Summary

"This trial compares two methods used during lung transplantation: routine use of a heart-lung machine and selective use based on patient oxygen levels. The goal is to see which method is better for patients with terminal

Who is the study for?
This trial is for patients with severe lung diseases like COPD or pulmonary fibrosis who are undergoing lung transplantation. It's not specified who can't join, but typically those with conditions that could complicate surgery or recovery might be excluded.
What is being tested?
The study compares two ways of using ECMO, a machine that helps breathe and circulate blood during lung transplant surgery: one group gets ECMO routinely, while the other only when it's necessary due to complications.
What are the potential side effects?
ECMO may increase risks of bleeding, infection, and clotting issues. However, compared to traditional heart-lung machines used in such surgeries, ECMO tends to have fewer complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for a lung transplant surgery.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My heart's right side is weak or not pumping well.
Select...
I need heart surgery in addition to my current treatment.
Select...
I have had an organ transplant before.
Select...
I have had a transplant involving multiple organs.
Select...
I cannot use standard blood thinners due to a bad reaction.
Select...
I had a lung transplant and needed heart-lung support during surgery.
Select...
I do not have severe pulmonary hypertension.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from the end of surgery up to 72 hours after surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and from the end of surgery up to 72 hours after surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ICU-free days
Secondary study objectives
Acute kidney injury (AKI)
Average financial costs and sustainability metrics
Duration of mechanical ventilation in hours
+11 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Routine ECMOExperimental Treatment1 Intervention
Routine ECMO during lung tansplant
Group II: On-demand ECMOActive Control1 Intervention
Selective, indication-based intraoperative cardiopulmonary support.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Routine ECMO
2022
N/A
~30

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor
377 Previous Clinical Trials
131,302 Total Patients Enrolled
~145 spots leftby Oct 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top